Fox Run Management L.L.C. Invests $680,000 in Henry Schein, Inc. $HSIC

Fox Run Management L.L.C. bought a new stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) during the 3rd quarter, HoldingsChannel reports. The institutional investor bought 10,246 shares of the company’s stock, valued at approximately $680,000.

A number of other hedge funds have also added to or reduced their stakes in HSIC. MAI Capital Management boosted its holdings in shares of Henry Schein by 7.5% during the 3rd quarter. MAI Capital Management now owns 2,061 shares of the company’s stock worth $137,000 after buying an additional 144 shares in the last quarter. CW Advisors LLC lifted its position in shares of Henry Schein by 2.8% during the 2nd quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after acquiring an additional 163 shares during the period. Truist Financial Corp lifted its position in shares of Henry Schein by 3.3% during the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after acquiring an additional 175 shares during the period. Simon Quick Advisors LLC boosted its stake in Henry Schein by 5.5% during the second quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after acquiring an additional 182 shares in the last quarter. Finally, Claret Asset Management Corp grew its holdings in Henry Schein by 6.3% in the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after purchasing an additional 187 shares during the period. 96.62% of the stock is currently owned by institutional investors.

Insider Transactions at Henry Schein

In other news, CEO Stanley M. Bergman sold 38,346 shares of the company’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $81.01, for a total value of $3,106,409.46. Following the completion of the sale, the chief executive officer owned 427,615 shares in the company, valued at $34,641,091.15. This represents a 8.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 1.08% of the stock is owned by corporate insiders.

Henry Schein Stock Performance

Shares of HSIC opened at $82.39 on Friday. The firm has a market capitalization of $9.45 billion, a P/E ratio of 25.20, a P/E/G ratio of 2.41 and a beta of 0.88. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The stock has a 50 day moving average price of $77.85 and a two-hundred day moving average price of $72.15. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.79 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last announced its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the previous year, the firm earned $1.19 earnings per share. Henry Schein’s quarterly revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts forecast that Henry Schein, Inc. will post 4.74 earnings per share for the current fiscal year.

Henry Schein News Roundup

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Reported quarterly results topped expectations (better EPS and revenue growth), which reinforces momentum in the stable dental market and was a primary driver for the stock rise. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Robert W. Baird upgraded HSIC, reflecting increased analyst confidence in growth/valuation after results. Upgrades can support further upside as they attract buy-side attention. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird
• Positive Sentiment: Leerink Partners published a bullish note forecasting strong price appreciation, adding to analyst-driven buying pressure. Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Positive Sentiment: Market reaction to the beat pushed HSIC to a new 12‑month high, signaling momentum traders and momentum-based funds may add exposure. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: A Yahoo/Finance piece notes analysts are re‑assessing HSIC’s growth profile and valuation — useful context but not an immediate directional catalyst. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Neutral Sentiment: Short‑interest data shows an anomalous report (0 shares / NaN change), which appears to be a reporting/data error and is unlikely to meaningfully affect near‑term trading.
• Negative Sentiment: CEO Stanley M. Bergman sold sizable blocks of stock on Feb. 26–27 (combined sale proceeds ~ $4.0M+), which can be perceived negatively by some investors as profit‑taking or reduced insider conviction. SEC filing: Insider sale filing

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on HSIC shares. Mizuho increased their price objective on shares of Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a research report on Wednesday. Barrington Research set a $97.00 price target on Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Henry Schein in a report on Monday, December 29th. Leerink Partners boosted their price objective on Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a report on Tuesday. Finally, Robert W. Baird set a $100.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Monday. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.